Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO versus SITAGLIPTIN AND METFORMIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO versus SITAGLIPTIN AND METFORMIN HCL.
JENTADUETO vs SITAGLIPTIN AND METFORMIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Jentadueto is a combination of linagliptin and metformin. Linagliptin inhibits DPP-4, increasing incretin levels (GLP-1, GIP) and enhancing glucose-dependent insulin secretion while suppressing glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), leading to glucose-dependent insulin secretion and decreased glucagon secretion. Metformin is a biguanide that reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
Administered orally twice daily with meals. Initial dose: one tablet JENTADUETO 5 mg/500 mg or 5 mg/1000 mg; subsequent titration based on glycemic response. Maximum daily dose: linagliptin 5 mg, metformin 2000 mg.
Initial: 50 mg sitagliptin/500 mg metformin twice daily or 50 mg/1000 mg twice daily (max 100 mg/2000 mg per day). Dose adjusted gradually based on glycemic response and tolerability.
None Documented
None Documented
Linagliptin: terminal t1/2 ~12 hours (long binding to DPP-4). Metformin: terminal t1/2 ~6.2 hours (renal impairment prolongs).
Sitagliptin: terminal t1/2 12.4 hours; Metformin: terminal t1/2 6.2 hours (prolonged to 17.6 hours in renal impairment). Combination: effective t1/2 ~7-12 hours, dosing adjusted for CrCl <45 mL/min.
Renal: linagliptin ~5% unchanged; metformin ~90% unchanged. Fecal: linagliptin ~80% (mostly unchanged). Biliary: minimal.
Sitagliptin: 79% excreted unchanged in urine via active tubular secretion and glomerular filtration; 13% metabolized with minimal biliary/fecal elimination (1% unchanged in feces). Metformin: 90% excreted unchanged in urine via active tubular secretion; 0% biliary/fecal.
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor